*International Journal of Computational and Experimental Science and ENgineering (IJCESEN)*

*Vol. 10-No.4 (2024) pp. 2270-2281*
*http://www.ijcesen.com*

***ISSN: 2149-9144***

*Copyright © IJCESEN*

**Research Article**

# The Role of Laboratory, Pharmacy, and Nutrition Services in the Comprehensive Management of Metabolic Syndrome A Narrative Review

**Rawan Abdulaziz ALNAKHLI[1]*, Mahmoud Faleh A ALNAKHLI[2], Wasmiah Faihan Muzwid ALANAZI[3], Hassan Gihzi ALHAJUOJ[4], Aldghmani, Abdulmajeed Eid M[5], Fahad Riffia Sh ALENEZI[6], Saud Saleh Mishal ALSHAMMARI[7], Mohammed Hashim Bador ALMADANI[8], Naif Suwailem Salem ALANAZI[9], Ali Yaseen Al BAHRANI[10], Abdullah Asir A. ALANAZI[11]**

[1] Specialist – Laboratory – New Najran General Hospital – Najran – Najran Region – Saudi Arabia
* **Corresponding Author Email**: ralnakhli1@moh.gov.sa - **ORCID:** 0009-0009-2745-0200

[2] Specialist – Laboratory – Maternity and Children Hospital Arar – Arar – Northern Borders Region – Saudi Arabia
**Email**:Mfalnakhli@moh.gov.sa - **ORCID:** 0009-0009-2745-9200

[3] Specialist – Laboratory – Prince Abdulaziz bin Musaed Hospital – Arar – Northern Borders Region – Saudi Arabia
**Email**:bs.bs1430@hotmail.com - **ORCID:** 0009-0009-2745-8200

[4] Specialist – Laboratory – Al-Safiyah Urgent Care Center – Madinah – Madinah Region – Saudi Arabia
**Email**:Hgalhajouj2@moh.gov.sa - **ORCID:** 0009-0009-2745-7200

[5] Technician – Laboratory – Prince Mutaib Bin Abdulaziz Hospital – Sakaka – Al-Jouf Region – Saudi Arabia
**Email**: m-g-id@hotmail.com - **ORCID:** 0009-0009-2745-6200

[6] Technician – Laboratory – Maternity and Children Hospital Arar – Arar – Northern Borders Region – Saudi Arabia
**Email**: - **ORCID:** 0009-0009-2745-2200Fahadraffaa@hotmail.com - **ORCID:** 0009-0009-2745-5200

[7] Pharmacy Technician – Rafha Central Hospital – Rafha – Northern Borders Region – Saudi Arabia
**Email**:Salshammari3@moh.gov.sa

[8] Pharmacy Technician – Al-Safiyah Urgent Care Center – Madinah – Madinah Region – Saudi Arabia
**Email**:m0o0.anb@gmail.com - **ORCID:** 0009-0009-2745-4200

[9] Pharmacy Technician – Eradah Complex and Mental Health – Arar – Northern Borders Region – Saudi Arabia
**Email**:nasoalanazi@moh.gov.sa - **ORCID:** 0009-0009-2745-3200

[10] Specialist – Food and Nutrition – Al Jaber Eye and ENT Hospital – Al-Ahsa – Eastern Region – Saudi Arabia
**Email**:Ali.mm1991@hotmail.com - **ORCID:** 0009-0009-2745-2200

[11] Specialist – Clinical Nutrition – Khafji General Hospital – Al-Khafji – Eastern Region – Saudi Arabia
**Email**:Aqkn995@gmail.com - **ORCID:** 0009-0009-2745-1200

**Article Info:**

**DOI:** 10.22399/ijcesen.3911
**Received :** 06 November 2024
**Accepted :** 28 December 2024

**Keywords**

Metabolic Syndrome X
Interdisciplinary Health Team
Clinical Laboratory Services
Pharmacy Services
Nutrition Therapy
Personalized Medicine

**Abstract:**

Metabolic syndrome, a constellation of interrelated risk factors including central obesity, insulin resistance, dyslipidemia, and hypertension, demands an integrated, multidisciplinary approach for effective management. Laboratory services form the backbone of diagnosis and monitoring, providing essential biochemical and hematologic markers—such as fasting glucose, HbA1c, lipid profile, liver enzymes, and inflammatory markers—that guide risk stratification and therapeutic decisions. Regular, standardized testing enables early detection of metabolic derangements, tracks response to interventions, and identifies medication-related adverse effects, thereby facilitating timely adjustments in care. Moreover, laboratory-driven population surveillance supports preventive strategies and the evaluation of programmatic outcomes across clinical settings. Pharmacy and nutrition services complement laboratory input by translating diagnostic information into individualized, evidence-based treatment plans. Pharmacists optimize medication regimens for glycemic control, blood pressure, and dyslipidemia while minimizing polypharmacy risks through medication reconciliation, adherence support, and counseling on side effects and drug–nutrient interactions. Nutrition professionals deliver tailored dietary interventions—focusing on caloric balance,

macronutrient composition, and culturally appropriate food choices—that target weight reduction, improve insulin sensitivity, and correct lipid abnormalities. When coordinated effectively, these three services foster a continuous cycle of assessment, intervention, and reassessment, enhancing patient engagement, improving clinical outcomes, and reducing long-term cardiometabolic complications associated with metabolic syndrome.

## 1. Introduction

Metabolic syndrome (MetS) represents one of the most significant and escalating public health challenges of the 21st century. It is not a single disease but a clustering of interrelated metabolic risk factors that collectively amplify an individual's propensity for developing atherosclerotic cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and all-cause mortality [1]. The core components of MetS, as defined by various international bodies such as the International Diabetes Federation (IDF) and the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), typically include central obesity, hypertension, dyslipidemia (characterized by elevated triglycerides and reduced high-density lipoprotein cholesterol), and impaired fasting glucose [2]. The global prevalence of MetS has reached pandemic proportions, affecting approximately one-quarter of the world's adult population, with variations across regions, ethnicities, and diagnostic criteria used [3]. This surge is inextricably linked to the adoption of sedentary lifestyles, diets high in processed foods and refined sugars, and the aging demographic profile of many nations, placing an immense and unsustainable burden on healthcare systems worldwide [4].

The clinical significance of MetS lies in its role as a potent multiplier of risk. The co-occurrence of its components creates a pathophysiological state far more dangerous than the sum of its individual parts. The syndrome is underpinned by two primary, intertwined pathophysiological pillars: insulin resistance and a chronic, low-grade inflammatory state, often exacerbated by visceral adiposity [5]. Insulin resistance impairs the body's ability to utilize glucose effectively, leading to compensatory hyperinsulinemia, which in turn promotes sodium retention, sympathetic nervous system activation, and dyslipidemia. Concurrently, dysfunctional adipose tissue, particularly visceral fat, acts as an active endocrine organ, releasing a cascade of pro-inflammatory cytokines (e.g., TNF-α, IL-6), adipokines, and free fatty acids into the portal circulation. This biochemical milieu further aggravates insulin resistance, promotes endothelial dysfunction, and drives the progression of atherosclerosis [6]. This complex network of dysregulation means that managing MetS requires a multifaceted approach that goes beyond simply treating each component in isolation.

Traditionally, the management of MetS has been perceived as the primary domain of the physician, who diagnoses the condition and prescribes pharmacological interventions such as antihypertensives, statins, or metformin. However, this siloed approach often fails to address the syndrome's root causes and multifaceted nature comprehensively. Effective and sustainable management necessitates a paradigm shift towards a collaborative, interdisciplinary model of care. This model integrates the unique expertise of various healthcare professionals to provide a holistic strategy encompassing accurate diagnosis, targeted pharmacological therapy, and foundational lifestyle modification [7]. Within this integrated framework, three critical support services emerge as indispensable pillars: the laboratory service, the pharmacy service, and the nutrition service. Each plays a distinct yet profoundly interconnected role in the entire patient journey, from initial risk stratification and diagnosis to ongoing management, monitoring, and patient education.

## The Indispensable Triad:

The comprehensive management of MetS can be conceptualized as a continuous cycle involving screening and diagnosis, intervention, and long-term monitoring and adherence. The laboratory, pharmacy, and nutrition services are integral to each stage of this cycle, forming a triad of diagnostic, therapeutic, and educational support.

First, the laboratory service is the cornerstone of objective diagnosis and risk stratification. The very definition of MetS is reliant on quantitative biochemical and clinical measurements. Laboratory professionals are responsible for providing accurate, precise, and timely results for key analytes, including plasma glucose, lipid profiles (total cholesterol, LDL-C, HDL-C, triglycerides), and often additional markers like glycated hemoglobin (HbA1c) and high-sensitivity C-reactive protein (hs-CRP) [8]. The reliability of these results is paramount, as they directly inform diagnostic decisions, classify the severity of the condition, and establish baseline values against which therapeutic efficacy is measured. Furthermore, the laboratory plays a crucial role in differential diagnosis, helping to rule out other endocrine disorders that can mimic

MetS, such as Cushing's syndrome or hypothyroidism [9]. Beyond initial diagnosis, the laboratory is essential for ongoing monitoring. Regular testing of lipid levels, liver and renal function (especially after initiating pharmacotherapy), and glycemic control allows clinicians to track disease progression, evaluate the effectiveness of lifestyle and drug interventions, and identify any adverse effects, thereby enabling timely adjustments to the management plan [10].

Second, the pharmacy service provides a critical bridge between the prescriber's treatment plan and the patient's safe and effective use of medications. Polypharmacy is common in MetS, as patients are often prescribed multiple agents to control blood pressure, lipids, and blood glucose. Pharmacists are the medication experts who ensure the appropriateness, safety, and efficacy of this complex regimen. Their role includes conducting comprehensive medication reviews to identify potential drug-drug interactions, duplications, or contraindications [11]. Moreover, pharmacists are on the front line of patient education, empowering individuals to understand the purpose of each medication, its proper administration, potential side effects, and the importance of adherence—a major challenge in chronic disease management. The emerging concept of clinical pharmacy services has expanded this role further, with pharmacists in some settings being granted prescribing authority or participating in collaborative drug therapy management, directly adjusting medications based on laboratory results and clinical outcomes [12]. This proactive involvement significantly enhances the quality of care and optimizes therapeutic outcomes.

Third, and perhaps most fundamentally, the nutrition service addresses the primary etiological driver of MetS: diet. While pharmacology manages the consequences of metabolic dysfunction, medical nutrition therapy (MNT) delivered by registered dietitians or clinical nutritionists targets the cause. Evidence overwhelmingly confirms that sustainable lifestyle modification, with diet at its core, is the first-line intervention for MetS and can, in many cases, prevent or delay the progression to T2DM and CVD [13]. Nutrition professionals conduct detailed dietary assessments to identify specific patterns contributing to the syndrome, such as excessive intake of refined carbohydrates, saturated and trans fats, and sugary beverages. They then develop individualized, culturally sensitive, and practical nutrition plans focused on promoting weight loss (particularly reduction of visceral fat), improving insulin sensitivity, and correcting dyslipidemia. These plans typically emphasize principles such as the Mediterranean or DASH diets, which are rich in fruits, vegetables, whole grains, lean proteins, and healthy fats [14]. Beyond mere prescription of a diet, nutritionists provide continuous counseling, motivation, and behavioral strategies to help patients implement and sustain these profound dietary changes, fostering long-term health and self-efficacy.

## Laboratory Diagnostics in Metabolic Syndrome:

The definitive diagnosis and effective management of metabolic syndrome (MetS) are fundamentally reliant on the objective data provided by laboratory medicine. Unlike many clinical conditions, MetS is a construct defined almost exclusively by quantitative measures, making the laboratory the essential starting point for identification, risk assessment, and ongoing monitoring. The role of the laboratory extends far beyond simple confirmation; it is central to screening at-risk populations, stratifying cardiovascular and diabetic risk, guiding therapeutic decisions, and evaluating the efficacy of interventions. The accuracy, precision, and standardization of laboratory testing are therefore paramount, as they form the evidential bedrock upon which all subsequent clinical actions are built [15]. This section delves into the core and emerging biomarkers used in MetS, outlines the principles of screening and diagnostic algorithms, and explores the critical function of laboratory data in risk stratification.

The diagnosis of MetS, as per consensus criteria from organizations like the International Diabetes Federation (IDF) and the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), hinges on the measurement of a core set of biochemical and clinical parameters. The essential laboratory panel includes a lipid profile—specifically measuring triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C)—and fasting plasma glucose (FPG) [16]. Central obesity, another key component, is often assessed using waist circumference, a anthropometric measure frequently performed in the clinic but sometimes within the purview of specialized laboratory or nursing staff. The fifth component, elevated blood pressure, is a clinical measurement. The core lipid abnormalities in MetS are characterized by hypertriglyceridemia (often ≥150 mg/dL) and low levels of HDL-C (<40 mg/dL in men, <50 mg/dL in women), a pattern driven by hepatic overproduction of very-low-density lipoprotein (VLDL) and impaired lipoprotein lipase activity secondary to insulin resistance [17]. Similarly, an elevated FPG (≥100 mg/dL) or a prior diagnosis of diabetes is a direct

reflection of the underlying insulin resistance that is the pathophysiological engine of the syndrome.

However, the utility of laboratory diagnostics in MetS transcends this basic diagnostic checklist. To truly appreciate an individual's risk, clinicians must often look to additional biomarkers that provide a deeper insight into the associated metabolic disarray and inflammatory state. Glycated hemoglobin (HbA1c) (≥5.7% indicates prediabetes) is now widely used as a more stable marker of chronic glycemic control and is included in some diagnostic guidelines [18]. Furthermore, a complete lipid panel also includes low-density lipoprotein cholesterol (LDL-C), which, while not a defining criterion for MetS, remains a primary target for pharmacotherapy to reduce cardiovascular risk. Often, the dyslipidemia of MetS presents with a predominance of small, dense LDL particles, which are more atherogenic than larger, buoyant LDL particles, though advanced lipid testing to identify this phenotype is not yet routine [19]. Liver function tests, particularly alanine aminotransferase (ALT), are crucial as they can indicate the presence of non-alcoholic fatty liver disease (NAFLD), considered the hepatic manifestation of MetS and an independent risk factor for cardiovascular morbidity [20].The most significant value of laboratory diagnostics may lie in its power for risk stratification. Identifying a patient with MetS is only the first step; determining their absolute risk for a future cardiovascular event or progression to diabetes is critical for tailoring the aggressiveness of therapy. Emerging biomarkers have expanded this capability. High-sensitivity C-reactive protein (hs-CRP), a marker of chronic low-grade inflammation, has been consistently shown to add predictive value beyond traditional risk factors. Elevated hs-CRP levels are common in MetS and are associated with an increased risk of myocardial infarction and stroke, helping to identify those who might benefit most from intensified statin therapy [21]. Similarly, elevated uric acid levels are frequently observed in MetS and are linked to both hypertension and insulin resistance, serving as an independent marker of adverse outcomes [22]. Other advanced markers like apolipoprotein B (ApoB), which provides a count of all atherogenic particles, and lipoprotein(a) are gaining traction for refining risk assessment in complex cases, particularly in those with significant dyslipidemia [23].The laboratory also plays an indispensable role in the differential diagnosis of MetS. It is essential to rule out other endocrine disorders that can present with a similar clinical picture. For instance, Cushing's syndrome can cause central obesity, hypertension, and glucose intolerance. Screening tests such as a 24-hour urinary free cortisol or a overnight dexamethasone suppression test are laboratory procedures used to exclude this condition [24]. Similarly, thyroid function tests (e.g., TSH) are necessary to rule out hypothyroidism, which can contribute to dyslipidemia and weight gain. This diagnostic precision ensures that secondary causes are not missed and that management is appropriately directed.Finally, the laboratory's role is cyclical, integral to the long-term monitoring and management of MetS. Once diagnosis is established and treatment initiated—whether through lifestyle modification or pharmacotherapy—serial laboratory testing is the primary tool for assessing response. Regular monitoring of FPG, HbA1c, and the lipid profile allows clinicians to gauge the effectiveness of dietary changes, exercise, and medications like metformin or statins. Furthermore, safety monitoring is a critical function. For example, initiating a statin or a fibrate necessitates baseline and periodic monitoring of liver transaminases and creatine kinase to detect potential hepatotoxicity or myositis [25]. Similarly, monitoring renal function is important for patients on antihypertensive medications like ACE inhibitors. Thus, the laboratory provides the continuous feedback loop that enables dynamic, evidence-based adjustments to the patient's management plan, ensuring both efficacy and safety in the long-term care of individuals with metabolic syndrome.

## Pharmacy Practice in Metabolic Syndrome:

The management of metabolic syndrome (MetS) is inherently complex, often requiring polypharmacy to address its individual components: dyslipidemia, hypertension, hyperglycemia, and the prothrombotic state. Within the interdisciplinary team, the pharmacist emerges as a pivotal figure, transforming a simple prescription into an optimized, safe, and effective therapeutic regimen. The role of pharmacy practice has evolved dramatically from a product-oriented focus to a patient-centered clinical service, encompassing comprehensive medication management, rigorous safety monitoring, and robust adherence support. This expanded scope is critical in MetS, where the synergistic use of multiple drug classes is necessary to mitigate the heightened risk of cardiovascular disease and type 2 diabetes. Pharmacists ensure that pharmacotherapy is not only evidence-based but also tailored to the individual patient’s needs, comorbidities, and risk profile, thereby maximizing benefits while minimizing adverse effects and drug interactions [26].The cornerstone of the pharmacist's role is conducting Comprehensive Medication Therapy Management (MTM). For a patient with MetS, this involves a meticulous review of all medications—prescription,

over-the-counter, and herbal supplements—to create a complete and accurate medication list. The pharmacist then assesses this regimen for several key issues: appropriateness for each MetS component, therapeutic effectiveness based on laboratory and clinical goals (e.g., achieving LDL-C, BP, and HbA1c targets), and the presence of potential safety concerns [27]. A primary focus is identifying and managing drug-drug interactions. For instance, the combination of a fibrate and a statin, while sometimes necessary for mixed dyslipidemia, increases the risk of severe myopathy and requires careful dose selection and patient education [28]. Similarly, non-dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem) can significantly increase the plasma concentration of statins metabolized by the CYP3A4 pathway, necessitating dose adjustments or choosing an alternative statin. By proactively identifying these interactions, pharmacists prevent adverse events that could compromise therapy and undermine patient confidence.Beyond safety, pharmacists are instrumental in optimizing pharmacotherapy to ensure patients achieve guideline-directed goals. This often involves collaborative drug therapy management (CDTM) agreements with physicians, allowing pharmacists to initiate, modify, or discontinue therapy based on predefined protocols and patient response [29]. For example, if a patient's blood pressure remains uncontrolled on an ACE inhibitor, a pharmacist under a CDTM protocol might add a low-dose thiazide diuretic, a combination supported by strong evidence from the ACC/AHA guidelines [30]. In managing statin therapy, pharmacists can titrate doses based on periodic LDL-C results to achieve the percent reduction appropriate for the patient's risk category. This proactive, protocol-driven approach improves efficiency in busy clinical settings and ensures timely intensification of therapy, closing the gap between clinical evidence and real-world practice. Furthermore, pharmacists possess the expertise to select the most cost-effective therapeutic options, such as recommending generic medications, which is a significant factor in improving long-term adherence [31].Perhaps the most challenging aspect of managing a chronic, asymptomatic condition like MetS is ensuring long-term medication adherence. Non-adherence is a pervasive problem that drastically reduces the real-world effectiveness of even the most well-conceived treatment plans. Pharmacists are uniquely positioned to address this challenge through targeted interventions. This begins with effective patient education, where pharmacists counsel patients on the purpose of each medication, its expected benefits, potential side effects, and the consequences of non-adherence, using clear, non-judgmental language [32]. They employ practical adherence strategies, such as synchronizing refill dates for all medications, recommending blister packs or pill organizers, and utilizing mobile health (mHealth) reminders for dose timing and refills [33]. By building a trusting relationship and providing continuous follow-up, pharmacists can identify barriers to adherence—whether they are cost-related, due to side effects (e.g., statin-associated muscle symptoms), or stemming from health literacy issues—and work with the patient and physician to find practical solutions.Managing actual or perceived adverse drug reactions (ADRs) is a critical skill that directly impacts adherence and persistence. A common example in MetS management is statin intolerance, often reported as muscle pain. Pharmacists play a key role in evaluating these reports, differentiating between true pharmacological effects and nocebo effects, and guiding appropriate management strategies. This may involve checking a creatine kinase (CK) level, recommending a trial of coenzyme Q10 supplementation, or discussing a "statin holiday" followed by rechallenge with the same or a different statin [34]. For patients experiencing a persistent dry cough from an ACE inhibitor, the pharmacist can advocate for a switch to an angiotensin II receptor blocker (ARB), which provides similar benefits without this bothersome side effect [35]. By effectively managing ADRs, pharmacists alleviate patient concerns, prevent unnecessary discontinuation of vital therapies, and maintain the integrity of the treatment regimen.The modern pharmacy practice model, particularly within ambulatory care clinics, positions the pharmacist as an accessible primary care extender. Integrated into the clinical team, pharmacists can conduct follow-up visits specifically for chronic disease management, focusing on medication efficacy, safety, and adherence. During these encounters, they can assess refill history, order necessary laboratory tests (e.g., lipid panels, renal function, liver enzymes) as per collaborative practice agreements, interpret the results, and adjust medications accordingly [36]. This model not only improves patient outcomes but also enhances clinic workflow by freeing up physician time for more complex diagnostic cases. The economic value of this clinical pharmacy service is also well-documented, demonstrating significant reductions in healthcare costs through improved disease control and decreased hospitalizations related to cardiovascular events [37]. In conclusion, pharmacy practice is indispensable in the comprehensive management of metabolic syndrome, providing the expertise necessary to navigate the complexities of polypharmacy, optimize therapeutic outcomes, and

empower patients to adhere to lifelong therapy, ultimately translating evidence-based guidelines into tangible patient benefits.

## Nutritional Interventions:

If pharmacotherapy addresses the consequences of metabolic dysfunction, medical nutrition therapy (MNT) delivered by registered dietitians targets its very core. Nutritional intervention is the unequivocal foundation and first-line strategy in the comprehensive management of metabolic syndrome (MetS). Its primary objectives are multifaceted: to reduce overall adiposity, particularly visceral fat; to improve insulin sensitivity; to correct atherogenic dyslipidemia; and to lower blood pressure. This is achieved not through short-term, restrictive "diets" but through the adoption of sustainable, health-promoting dietary patterns that create a negative energy balance while ensuring optimal nutrient intake. The evidence overwhelmingly demonstrates that structured nutritional interventions can prevent or delay the progression from MetS to type 2 diabetes and cardiovascular disease, with a efficacy comparable to, or in some cases surpassing, that of pharmacologic agents [38]. This section explores the evidence-based dietary patterns effective for MetS, the critical role of caloric management for weight loss, and the ongoing scientific dialogue regarding macronutrient balance.The most robust evidence for managing MetS supports the adoption of holistic dietary patterns rather than a focus on isolated nutrients. Two patterns stand out for their extensive research backing and demonstrated cardiometabolic benefits: the Dietary Approaches to Stop Hypertension (DASH) diet and the Mediterranean diet. The DASH diet, originally designed to lower blood pressure, emphasizes high intake of fruits, vegetables, whole grains, and low-fat dairy products; includes lean meats, fish, poultry, nuts, and beans; and is restricted in sodium, sugar-sweetened beverages, and red meats. Numerous studies have shown that adherence to the DASH diet not only reduces hypertension but also improves insulin sensitivity and lipid profiles, effectively addressing multiple components of MetS simultaneously [39]. Similarly, the traditional Mediterranean diet, characterized by an abundance of plant-based foods (fruits, vegetables, whole grains, legumes, nuts), olive oil as the principal source of fat, moderate consumption of fish and poultry, and low intake of red meat and sweets, has proven highly effective. The PREDIMED trial, a landmark study, demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil or nuts significantly reduced the incidence of major cardiovascular events among individuals at high risk, many of whom had MetS [40]. These patterns are effective because they are naturally rich in fiber, antioxidants, and unsaturated fats while being low in processed carbohydrates, saturated fats, and sodium. The initiation of any nutritional intervention for an overweight or obese individual with MetS must begin with caloric management to achieve negative energy balance and clinically significant weight loss. It is well-established that a modest weight loss of 5-10% of total body weight can produce profound improvements in all features of the syndrome: reducing intra-abdominal fat, lowering blood pressure, improving glycemic control, and decreasing triglyceride levels while raising HDL-C [41]. The fundamental principle is that energy intake must be less than energy expenditure. This can be accomplished through various methods, and the "best" diet is ultimately the one that a patient can adhere to long-term. Strategies include structured portion control, prescribed daily caloric deficits (typically 500-750 kcal/day), or the use of food replacement strategies. The role of the nutritionist is crucial in calculating appropriate calorie goals, educating patients on reading food labels, estimating portion sizes, and helping them identify and modify high-calorie dietary behaviors. This process is not merely prescriptive but involves collaborative goal-setting and continuous support to navigate real-world challenges, making caloric management a sustainable lifestyle change rather than a temporary fix [42].Beyond total caloric intake and overall dietary patterns, the specific balance of macronutrients—carbohydrates, fats, and proteins—has been a subject of intense research and debate in nutritional science as it pertains to MetS. The traditional low-fat approach has largely been supplanted by a more nuanced understanding that emphasizes the *quality* of macronutrients over their absolute quantity. Regarding carbohydrates, the focus has shifted from simply reducing total carbs to eliminating refined sugars and highly processed grains and increasing intake of high-fiber, low-glycemic index carbohydrates (e.g., non-starchy vegetables, legumes, whole oats). Dietary fiber, particularly soluble fiber, plays a vital role by slowing gastric emptying, blunting postprandial glucose spikes, and improving satiety, which aids in weight management [43]. Furthermore, soluble fiber can bind to bile acids in the intestine, promoting their excretion and thereby forcing the liver to use circulating cholesterol to synthesize new bile acids, which contributes to lowering LDL-C levels [44].

The role of dietary fat has been rehabilitated, with a clear distinction made between harmful and beneficial fats. The imperative is to strictly limit intake of *trans* fats and reduce saturated fats (found in red meat, butter, and full-fat dairy), replacing

them with unsaturated fats. Monounsaturated fatty acids (MUFAs), abundant in olive oil, avocados, and nuts, and polyunsaturated fatty acids (PUFAs), including omega-3 fatty acids found in fatty fish (e.g., salmon, mackerel), flaxseeds, and walnuts, have demonstrated positive effects on the lipid profile and insulin sensitivity [45]. Omega-3 PUFAs, in particular, are potent triglycerides-lowering agents. The debate on protein intake centers on source and quantity. Some evidence suggests that moderately higher protein intake (20-30% of total calories) can enhance satiety, preserve lean muscle mass during weight loss, and may impart a slight metabolic advantage [46]. However, the source is critical; emphasis should be placed on plant-based proteins (legumes, lentils), fish, and lean poultry over red and processed meats, which are associated with increased cardiovascular risk [47].

Finally, effective nutritional intervention extends beyond mere prescription. It requires skilled behavioral counseling to facilitate lasting change. Nutritionists employ techniques from motivational interviewing and cognitive-behavioral therapy to help patients set realistic goals, self-monitor their food intake, identify triggers for unhealthy eating, and develop problem-solving skills [48]. This ongoing support is essential for overcoming barriers to adherence and preventing relapse. In conclusion, nutritional therapy is a powerful, non-pharmacological weapon against metabolic syndrome. Its effectiveness lies in a multi-pronged approach: advocating for evidence-based dietary patterns like the Mediterranean or DASH diet, implementing strategic caloric restriction for weight loss, and optimizing macronutrient quality by emphasizing fiber-rich carbohydrates, unsaturated fats, and lean protein sources. When delivered by skilled professionals within an interdisciplinary team, it empowers patients to take control of their health and achieve sustainable metabolic improvement [49].

## Dietary Counseling and Behavior Change:

The development of an evidence-based, technically perfect dietary plan is a necessary but insufficient step in the successful long-term management of metabolic syndrome (MetS). The most significant challenge, and the ultimate determinant of success, lies in facilitating sustained patient adherence to nutritional recommendations. This is where the role of clinical nutrition services transcends mere prescription and enters the realm of behavioral science. Registered dietitians and nutritionists are uniquely trained to provide structured dietary counseling that addresses the complex psychological, social, and environmental factors influencing eating behaviors. Their expertise is critical in moving patients from a state of knowledge (understanding what to eat) to one of action (consistently making healthy choices) and maintenance (adhering to these choices long-term). This process is fundamental to achieving and preserving the metabolic improvements initiated by dietary change, thereby preventing disease progression and complications [50].

Effective dietary counseling is a patient-centered, collaborative process built on a foundation of trust and empathy. It begins with a comprehensive assessment that extends far beyond a simple 24-hour dietary recall. The nutritionist explores the patient's medical history, lifestyle, cultural and ethnic food preferences, socioeconomic constraints, cooking skills, work schedule, and readiness to change. This holistic understanding is crucial for co-creating an individualized plan that is not only medically appropriate but also practical, culturally relevant, and personally acceptable to the patient [51]. Imposing a rigid, standardized diet that ignores a patient's lifestyle and food culture is a recipe for failure. Instead, the counselor works *with* the patient to adapt evidence-based patterns like the Mediterranean or DASH diet into their existing framework, identifying specific, achievable swaps and modifications rather than advocating for a complete and overwhelming overhaul of their current diet.To facilitate meaningful and lasting behavior change, nutritionists employ established counseling techniques and theoretical models. Motivational Interviewing (MI) is a cornerstone of this approach. MI is a collaborative, goal-oriented style of communication designed to strengthen a person's own motivation and commitment to change by exploring and resolving ambivalence [52]. Instead of lecturing or confronting, the nutritionist using MI asks open-ended questions, listens reflectively, and affirms the patient's strengths and efforts. They help the patient articulate their own reasons for wanting to change—whether it's having more energy to play with grandchildren, avoiding diabetes medication, or simply feeling better—which is a far more powerful motivator than external pressure from a healthcare provider. This technique is particularly effective in MetS, where patients may not feel immediate symptoms and thus struggle with intrinsic motivation.Another critical framework is the use of SMART goals (Specific, Measurable, Achievable, Relevant, Time-bound). Rather than setting a vague objective like "eat healthier," the nutritionist guides the patient to set a highly specific short-term goal, such as "I will add one serving of vegetables to my dinner at least five nights this week" or "I will replace my afternoon soda with sparkling water on weekdays" [53]. This approach

breaks down the daunting task of "dieting" into small, manageable steps, creating a series of achievable victories that build self-efficacy and momentum. The nutritionist provides ongoing support and accountability, helping the patient problem-solve obstacles that arise. For example, if a patient struggles with late-night snacking, the counselor might help them develop strategies such as brushing their teeth immediately after dinner, preparing a healthy alternative like a piece of fruit, or engaging in a distracting activity.The environment in which a patient lives and works exerts a powerful influence on their dietary choices. A key role of nutrition services is to help patients engineer their personal environments to support their goals. This involves practical strategies such as encouraging patients to shop from a grocery list, avoid shopping when hungry, and keep tempting foods out of the home while ensuring healthy options are visible and easily accessible [54]. Counseling also addresses eating behaviors themselves, teaching mindful eating practices. Patients are encouraged to eat slowly without distractions (e.g., turning off the TV), to recognize physical hunger and satiety cues, and to differentiate between physical hunger and emotional triggers for eating, such as stress, boredom, or sadness [55]. By developing awareness around these triggers, patients can learn to develop non-food-related coping mechanisms, which is essential for breaking the cycle of emotional eating that often derails weight management efforts.

Long-term control of MetS is a marathon, not a sprint, and nutrition services provide the essential continuous support system. This involves scheduled follow-up appointments to monitor progress, reassess goals, and provide ongoing encouragement. The nutritionist acts as a reliable source of information, helping patients navigate real-world challenges like dining out, attending social gatherings, and reading food labels accurately [56]. They can also facilitate access to additional resources, such as community cooking classes or food assistance programs, addressing barriers beyond the patient's immediate control. The effectiveness of this continuous, multi-contact model is well-documented. Studies consistently show that patients who receive ongoing nutrition counseling—ranging from three to twelve sessions or more—achieve significantly greater improvements in weight, glycemic control, and lipid profiles compared to those who receive a single session of advice or standard care [57]. This underscores that lasting change is a process that requires reinforcement, adjustment, and long-term support, solidifying the role of the nutrition professional as an indispensable member of the healthcare team for chronic disease management.

Personalized Medicine and Laboratory-Guided Therapy:

The traditional approach to managing metabolic syndrome (MetS) has often employed a one-size-fits-all strategy, applying general dietary and pharmacological guidelines uniformly across a highly heterogeneous patient population. However, the variable clinical presentation and underlying pathophysiology of MetS demand a more nuanced approach. The paradigm is now decisively shifting towards personalized medicine, which aims to tailor preventive and therapeutic interventions to the individual characteristics of each patient. At the heart of this evolution lies the laboratory, which provides the critical objective data necessary to move from population-based guidelines to individualized management plans. By integrating detailed phenotypic data from advanced laboratory biomarkers with potential genotypic information, clinicians can stratify risk more precisely, select the most effective therapies, and monitor response with greater accuracy, thereby optimizing outcomes and avoiding unnecessary treatments [58]. This section explores the transition from a generalized to a personalized approach in MetS management, focusing on the role of laboratory-guided therapy in creating tailored interventions.The foundation of personalized management in MetS is a deep and detailed phenotypic characterization that goes beyond the five standard diagnostic criteria. Advanced laboratory testing provides a window into the specific metabolic derangements driving the syndrome in an individual. For instance, a standard lipid panel (LDL-C, HDL-C, TG) can be supplemented with advanced lipoprotein analysis. Tests such as apolipoprotein B (ApoB) measurement, which quantifies the total number of atherogenic particles, or nuclear magnetic resonance (NMR) spectroscopy, which can identify the predominance of small, dense LDL particles, provide a much more accurate assessment of cardiovascular risk than LDL-C alone [59]. Similarly, beyond fasting glucose and HbA1c, assessments of insulin resistance itself, such as the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) or postprandial glucose and insulin responses, can identify individuals with significant beta-cell dysfunction who may benefit from earlier or more aggressive intervention [60]. This granular laboratory profiling allows for the identification of distinct phenotypes, such as those with severe atherogenic dyslipidemia versus those with predominant hypertension or impaired glucose metabolism, enabling targeted therapy.This detailed phenotypic information directly guides the selection and intensification of pharmacotherapy. In dyslipidemia management, for example, the choice

of agent can be tailored to the specific lipid abnormality. A patient with isolated high triglycerides might be best initiated on a fibrate or high-dose omega-3 fatty acids, while a patient with elevated ApoB and a predominance of small, dense LDL would derive greater benefit from a high-intensity statin, perhaps combined with ezetimibe [61]. Furthermore, laboratory monitoring is essential for guiding dose titration. The required percentage reduction in LDL-C is risk-stratified, and serial lipid panels are used to titrate statin doses until the patient's personalized target is achieved. In glycemic control, the choice between metformin, a GLP-1 receptor agonist, or an SGLT2 inhibitor can be influenced by the patient's body weight, risk of hypoglycemia, and the presence of co-morbidities like heart failure or chronic kidney disease, all of which are informed by laboratory and clinical data [62]. This ensures that the right drug is chosen for the right patient at the right time.

The principle of personalization extends profoundly into nutritional interventions. The concept of "precision nutrition" challenges the notion that there is a single, ideal diet for all individuals with MetS. Emerging research suggests that inter-individual variability in factors such as genetics, gut microbiota composition, and metabolic phenotype (e.g., insulin-secretory capacity) can significantly influence responses to specific macronutrients [63]. For example, individuals with high insulin resistance may see a greater benefit from a moderately lower carbohydrate diet that minimizes postprandial glucose excursions, while others might thrive on a higher complex carbohydrate, lower fat diet [64]. Laboratory-guided therapy is key here. Continuous glucose monitoring (CGM), though not yet routine, provides real-time, personalized data on an individual's glycemic response to specific foods, empowering the dietitian and patient to collaboratively identify which so-called "healthy" foods may cause undesirable spikes and should be modified or avoided [65]. This moves dietary advice from generic recommendations to highly personalized guidance.The future of personalized management in MetS points toward the integration of genotypic data with phenotypic laboratory results. Pharmacogenomics, the study of how genes affect a person's response to drugs, is becoming increasingly relevant. Genetic polymorphisms can influence the metabolism, efficacy, and risk of adverse effects of commonly used medications. For instance, variations in the *SLCO1B1* gene are associated with an increased risk of statin-induced myopathy, and pre-emptive genotyping could guide the selection of a specific statin or dose for susceptible individuals [66]. While not yet standard of care for MetS, the falling cost of genetic testing and growing evidence base suggest that pharmacogenomic guidance will become a more common tool to enhance drug safety and efficacy in the future, further refining the personalized approach [67].Ultimately, the goal of personalized, laboratory-guided therapy is to create a dynamic and iterative feedback loop. The management plan is not static but is continuously refined based on the patient's response, as measured by serial laboratory testing and clinical evaluation. This process allows for the early identification of non-responders to a particular therapy, prompting a swift change in strategy rather than persisting with an ineffective treatment. It empowers clinicians to practice proactive, pre-emptive medicine by identifying high-risk individuals before overt disease manifests. By embracing this tailored approach, the interdisciplinary team can maximize the therapeutic benefit, minimize the risk of adverse effects, improve patient adherence through more effective interventions, and ultimately, achieve superior long-term outcomes in the complex and multifactorial management of metabolic syndrome [68].

**Conclusion**

The management of metabolic syndrome is a complex, lifelong endeavor that cannot be effectively addressed through a singular disciplinary lens. This narrative review has delineated the indispensable and interconnected roles of laboratory, pharmacy, and nutrition services in constructing a comprehensive and effective management strategy. The laboratory provides the essential objective data that forms the bedrock of diagnosis, personalized risk assessment, and the critical feedback loop for monitoring therapeutic efficacy and safety. The pharmacist translates this data into action, optimizing complex drug regimens to achieve guideline-directed targets while managing interactions and side effects that threaten adherence. Finally, the nutritionist addresses the syndrome's foundational causes, empowering patients with the knowledge and behavioral tools to implement sustainable dietary changes that improve metabolic health.The overarching theme that emerges is that the synergy between these three pillars is paramount. Diagnostic insights from the laboratory should directly inform pharmacological decisions by the clinician and pharmacist, which are then powerfully augmented by the lifestyle interventions orchestrated by the nutritionist. This collaborative model facilitates a shift from a reactive, generic approach to a proactive, personalized, and pre-emptive strategy. Future efforts must focus on breaking down professional silos, implementing integrated care models that formally include these services, and leveraging technology to enhance communication among the team and engagement

with the patient. Ultimately, the optimal management of metabolic syndrome depends on this triad of services working in concert to guide, treat, and support the patient, thereby reducing the global burden of cardiovascular disease and diabetes and paving the way for a new standard of chronic disease care.

## Author Statements:

- **Ethical approval:** The conducted research is not related to either human or animal use.
- **Conflict of interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
- **Acknowledgement:** The authors declare that they have nobody or no-company to acknowledge.
- **Author contributions:** The authors declare that they have equal right on this paper.
- **Funding information:** The authors declare that there is no funding to be acknowledged.
- **Data availability statement:** The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

## References

[1] Witchel S.F., Oberfield S.E., Peña A.S, (2019). Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. *J. Endocr. Soc.* 3:1545–1573. doi: 10.1210/js.2019-00078.

[2] Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., Janssen O.E., Legro R.S., Norman R.J., Taylor A.E., et al., (2006). Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. J. Clin. Endocrinol. *Metab.* 91:4237–4245. doi: 10.1210/jc.2006-0178.

[3] Rajiah K., Sivarasa S., Maharajan M.K, (2021). Impact of Pharmacists' Interventions and Patients' Decision on Health Outcomes in Terms of Medication Adherence and Quality Use of Medicines among Patients Attending Community Pharmacies: A Systematic Review. Int. J. Environ. Res. *Public Health.* 18:4392. doi: 10.3390/ijerph18094392.

[4] Ferrar i R, (2015). Writing Narrative Style Literature Reviews. *Med. Writ.* 24:230–235. doi: 10.1179/2047480615Z.000000000329.

[5] Gambineri A., Patton L., Altieri P., Pagotto U., Pizzi C., Manzoli L., Pasquali R, (2012). Polycystic Ovary Syndrome Is a Risk Factor for Type 2 Diabetes. *Diabetes.* 61:2369–2374. doi: 10.2337/db11-1360.

[6] Helvaci N., Yildiz B.O, (2023). Current and Emerging Drug Treatment Strategies for Polycystic Ovary Syndrome. Expert Opin. *Pharmacother.* 24:105–120. doi: 10.1080/14656566.2022.2108702.

[7] Schumacher P.M., Becker N., Tsuyuki R.T., Griese-Mammen N., Koshman S.L., McDonald M.A., Bouvy M., Rutten F.H., Laufs U., Böhm M., et al., (2021). The Evidence for Pharmacist Care in Outpatients with Heart Failure: A Systematic Review and Meta-Analysis. *ESC Heart Fail.* 8:3566–3576. doi: 10.1002/ehf2.13508.

[8] Christ J.P., Cedars M.I, (2023). Current Guidelines for Diagnosing PCOS. *Diagnostics*. 13:1113. doi: 10.3390/diagnostics13061113.

[9] Sanchez-Garrido M.A., Tena-Sempere M., (2020). Metabolic Dysfunction in Polycystic Ovary Syndrome: Pathogenic Role of Androgen Excess and Potential Therapeutic Strategies. Mol. *Metab.* 35:100937. doi: 10.1016/j.molmet.2020.01.001.

[10] Stuhec M., Tement V, (2021). Positive Evidence for Clinical Pharmacist Interventions during Interdisciplinary Rounding at a Psychiatric Hospital. *Sci. Rep*. 11:13641. doi: 10.1038/s41598-021-92909-2.

[11] Salari N., Nankali A., Ghanbari A., Jafarpour S., Ghasemi H., Dokaneheifard S., Mohammadi M, (2024). Global Prevalence of Polycystic Ovary Syndrome in Women Worldwide: A Comprehensive Systematic Review and Meta-Analysis. Arch. Gynecol. *Obstet*. 310:1303–1314. doi: 10.1007/s00404-024-07607-x.

[12] Anbar H.S., Vahora N.Y., Shah H.I., Azam M.M., Islam T., Hersi F., Omar H.A., Dohle W., Potter B.V.L., El-Gamal M.I, (2023). Promising Drug Candidates for the Treatment of Polycystic Ovary Syndrome (PCOS) as Alternatives to the Classical Medication Metformin. Eur. J. *Pharmacol.* 960:176119. doi: 10.1016/j.ejphar.2023.176119.

[13] Mumusoglu S., Yildiz B.O, (2020). Polycystic Ovary Syndrome Phenotypes and Prevalence: Differential Impact of Diagnostic Criteria and Clinical versus Unselected Population. Curr. Opin. Endocr. *Metab. Res.* 12:66–71. doi: 10.1016/j.coemr.2020.03.004.

[14] Sachdeva G., Gainder S., Suri V., Sachdeva N., Chopra S, (2019). Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and Their Response to Clomiphene. Indian J. Endocrinol. *Metab.* 23:326. doi: 10.4103/ijem.IJEM_30_19.

[15] PCNE The PCNE Classification V 9.1 2020.

[16] Barber T.M., Hanson P., Weickert M.O., Franks S, (2019). Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. Clin. Med. Insights Reprod. *Health.* 13:1179558119874042. doi: 10.1177/1179558119874042.

[17] Espinosa M.E., Sánchez R., Otzen T., Bautista-Valarezo E., Aguiar S., Corrales-Gutierrez I., Leon-Larios F., Manterola C, (2024). Phenotypic Characterization of Patients with Polycystic Ovary

Syndrome in a Population from the Ecuadorian Andes: A Cross-Sectional Study. *J. Clin. Med.* 13:2376. doi: 10.3390/jcm13082376.

[18] Ahmed A., Saqlain M., Tanveer M., Blebil A.Q., Dujaili J.A., Hasan S.S, (2021). The Impact of Clinical Pharmacist Services on Patient Health Outcomes in Pakistan: A Systematic Review. *BMC Health Serv. Res.* 21:859. doi: 10.1186/s12913-021-06897-0.

[19] Sirmans S.M., Pate K.A, (2013). Epidemiology, Diagnosis, and Management of Polycystic Ovary Syndrome. Clin. *Epidemiol.* 6:1–13. doi: 10.2147/CLEP.S37559.

[20] Rashid R., Mir S.A., Kareem O., Ali T., Ara R., Malik A., Amin F., Bader G.N, (2022). Polycystic Ovarian Syndrome-Current Pharmacotherapy and Clinical Implications. Taiwan. J. Obstet. *Gynecol.* 61:40–50. doi: 10.1016/j.tjog.2021.11.009.

[21] Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R., Welt C.K, (2013). Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. *Metab*. 98:4565–4592. doi: 10.1210/jc.2013-2350.

[22] Kim J.J., (2024). Obesity and Polycystic Ovary Syndrome. *J. Obes. Metab. Syndr*. 33:289–301. doi: 10.7570/jomes24035.

[23] Coons L.M., Loucks J, (2023). Role and Impact of a Clinical Pharmacist in an Ambulatory Reproductive Endocrinology and Infertility Clinic. Am. *J. Health Syst. Pharm.* 80:1206–1212. doi: 10.1093/ajhp/zxad133.

[24] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome. (2024). Fertil. *Steril.* 81:19–25. doi: 10.1016/j.fertnstert.2003.10.004.

[25] Ye J. Role of insulin in the pathogenesis of free fatty acid-induced insulin resistance in skeletal muscle. (2007) Endocr. Metab. Immune Disord. *Drug Targets.* 7:65–74. doi: 10.2174/187153007780059423

[26] McCracken E, Monaghan M, Sreenivasan S, (2018). Pathophysiology of the metabolic syndrome. *Clin. Dermatol.* 36:14–20. doi: 10.1016/j.clindermatol.2017.09.004

[27] Huth C, Pigeon É, Riou M-È, St-Onge J, Arguin H, Couillard E, et al., (2016). Fitness, adiposopathy, and adiposity are independent predictors of insulin sensitivity in middle-aged men without diabetes. *J. Physiol. Biochem.* 72:435–44. doi: 10.1007/s13105-016-0488-2

[28] Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al., (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA.* 288:2709–16. doi: 10.1001/jama.288.21.2709

[29] Vaidya RA, Desai S, Moitra P, Salis S, Agashe S, Battalwar R, et al., (2023). Hyperinsulinemia: an early biomarker of metabolic dysfunction. Front. *Clin. Diabetes Healthc.* 4:1159664. doi: 10.3389/fcdhc.2023.1159664

[30] Agyemang-Yeboah F, Eghan BA, Annani-Akollor ME, Togbe E, Donkor S, Afranie BO, (2019). Evaluation of metabolic syndrome and its associated risk factors in type 2 diabetes: A descriptive cross-sectional study at the Komfo Anokye Teaching Hospital, Kumasi, Ghana. *BioMed. Res. Int.* 4562904. doi: 10.1155/2019/4562904

[31] Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al., (2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care.* 24:683–9. doi: 10.2337/diacare.24.4.683

[32] Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, et al., (2008). Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler. *Thromb. Vasc. Biol.* 28:1039–49. doi: 10.1161/ATVBAHA.107.159228

[33] Catalano KJ, Maddux BA, Szary J, Youngren JF, Goldfine ID, Schaufele F, (2014). Insulin resistance induced by hyperinsulinemia coincides with a persistent alteration at the insulin receptor tyrosine kinase domain. *PloS One*. 9:e108693. doi: 10.1371/journal.pone.0108693

[34] Mottillo S, Filion KB, Genest J, Genest J, Joseph L, Pilote L, et al., (2010). The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J. Am. Coll. *Cardiol*. 56:1113–32. doi: 10.1016/j.jacc.2010.05.034

[35] Charkos TG, Getnet M, (2023). Metabolic syndrome in patients with type 2 diabetes mellitus at Adama Hospital Medical College, Ethiopia: a hospital-based cross-sectional study. Front. Clin. *Diabetes Healthc.* 4:1165015. doi: 10.3389/fcdhc.2023.1165015

[36] Eckel RH, Grundy SM, Zimmet PZ, (2005). The metabolic syndrome. *Lancet.* 365:1415–28. doi: 10.1016/S0140-6736(05)66378-7

[37] Kanjilal S, Shanker J, Rao VS, Khadrinarasimhaih NB, Mukherjee M, Iyengar SS, et al., (2008). Prevalence and component analysis of metabolic syndrome: an Indian atherosclerosis research study perspective. Vasc. *Health Risk Manage*. 4:189–97. doi: 10.2147/vhrm.2008.04.01.189

[38] Moore JX, Chaudhary N, Akinyemiju T, (2017). Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. *Prev. Chronic Dis*. 14:160287. doi: 10.5888/pcd14.160287

[39] Ellulu MS, Khaza'ai H, Rahmat A, Patimah I, Abed Y, (2016). Obesity can predict and promote systemic inflammation in healthy adults. *Int. J. Cardiol*. 215:318–24. doi: 10.1016/j.ijcard.2016.04.089

[40] Foster-Powell K, Holt SH, Brand-Miller JC, (2016). International table of glycemic index and glycemic load values. *Am J Clin Nutr*. 76:5–56. doi: 10.1093/ajcn/76.1.5.

[41] Hepler CD, Strand LM, (1990). Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 47(3):533–43.

[42] Tumkur A, Pm M, Shetty R, Naik A, (2012). Pharmaceutical care: need of the hour in India. *J*

*Young Pharmacists.* 4:282–6. doi: 10.4103/0975-1483.104374.

[43] Bantle JP, Wylie-Rosett J, Albright A, Apovian CM, Clark NG, (2008). American Diabetes Association et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. *Diabetes Care*. 31(Suppl. 1):S61–S78. doi: 10.2337/dc08-S061.

[44] Kaveeshwar S, Cornwall J, (2014). The current state of diabetes mellitus in India. *Australas Med J*. 7(1):45–48. doi: 10.4066/AMJ.2014.1979.

[45] Suckling RJ, He FJ, Macgregor GA, (2010). Altered dietary salt intake for preventing and treating diabetic kidney disease. *Cochrane Database Syst Rev*. 12:Cd006763. doi: 10.1002/14651858.CD006763.pub2.

[46] JD K. (2001). National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. *Am J Kidney Dis*. 37(1 Suppl 2):S66–70. doi: 10.1053/ajkd.2001.20748.

[47] Nugent R. (2008). Chronic diseases in developing countries health and economic burdens. *New York Academy of Sciences.* 1136:70–79. doi: 10.1196/annals.1425.027.

[48] Analava Mitra. (2003). Food Habits: Some Relationship to Diabetes and Heart Diseases. *Anthropologist Special* Vol(3). 109–122.

[49] Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. (2007). Epidemiology of type 2 diabetes: Indian scenario. *Indian J Med Res*. 125(3):217–30.

[50] Luthra D. (2010). A link between stress and diabetes. *Webmedcentral Psychiatry*. 1(10):Wmc001095.

[51] American Diabetes Association. (2012). Standards of medical care in diabetes—2013. *Diabetes Care.* 36:S11–66. doi: 10.2337/dc13-S011.

[52] Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. (2012). Pharmacists' interventions in the management of patients with chronic kidney disease: a systematic review. *Nephrol Dial Transplant.* 27(1):276–292. doi: 10.1093/ndt/gfr287.

[53] Suckling RJ, He FJ, Macgregor GA, (2010). Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 12:Cd006763. doi: 10.1002/14651858.CD006763.pub2.

[54] Kc D, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K, (2009). Microvascular and macrovascular complications associated with diabetes in children and adolescents. *Pediatr Diabetes.* 10(Suppl. 12):195–203. doi: 10.1111/j.1399-5448.2009.00576.x.

[55] Fowler MJ. (2008). Microvascular and macrovascular complications of diabetes. Clin Diabetes. 26:2.

[56] Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al., (2004). Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. *Circulation*. 110:1245–1250. doi: 10.1161/01.CIR.0000140677.20606.0E

[57] Després JP, Lemieux I., (2006). Abdominal obesity and metabolic syndrome. *Nature*. 444:881–887. doi: 10.1038/nature05488

[58] Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. (2014). Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. *Diabetes Res Clin Pract.* 105:141–150. doi: 10.1016/j.diabres.2014.04.006

[59] Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr, Wilson PW. (2005). Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. *Diabetes.* 54:3252–3257. doi: 10.2337/diabetes.54.11.3252

[60] Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al., (2007). Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. *J Am Coll Cardiol*. 49:403–414. doi: 10.1016/j.jacc.2006.09.032

[61] Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, et al., (2015). The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome. *J Am Coll Cardiol*. 66:1050–1067. doi: 10.1016/j.jacc.2015.06.1328

[62] Grundy SM. (2008). Metabolic syndrome pandemic. *Arterioscler Thromb Vasc Biol.* 28:629–636. doi: 10.1161/ATVBAHA.107.151092

[63] Kim LJ, Nalls MA, Eiriksdottir G, Sigurdsson S, Launer LJ, Koster A, et al. (2011). Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik study. *Obesity (Silver Spring).* 19:1265–1271. doi: 10.1038/oby.2010.291

[64] Esser N, Paquot N, Scheen AJ, (2015). Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. *Expert Opin Investig Drugs*. 24:283–307. doi: 10.1517/13543784.2015.974804

[65] Dommermuth R, Ewing K., (2018). Metabolic syndrome: systems thinking in heart disease. Prim Care. 45:109–129. doi: 10.1016/j.pop.2017.10.003Stenholm S, Koster A, Alley DE, Visser M, Maggio M, Harris TB, et al., (2010). Adipocytokines and the metabolic syndrome among older persons with and without obesity: the InCHIANTI study. *Clin Endocrinol (Oxf).* 73:55–65. doi: 10.1111/j.1365-2265.2009.03742.x

[66] Grundy SM., (2016). Overnutrition, ectopic lipid and the metabolic syndrome. *J Investig Med*. 64:1082–1086. doi: 10.1136/jim-2016-000155

[67] D'Adamo E, Marcovecchio ML, Giannini C, Capanna R, Impicciatore M, Chiarelli F, et al., (2010). The possible role of liver steatosis in defining metabolic syndrome in prepubertal children. *Metabolism*. 59:671–676. doi: 10.1016/j.metabol.2009.09.012